Cubist Pharmaceuticals, Inc submitted two Investigational New Drug Applications (INDs) with the US FDA on December 23rd. The INDs signify the company's intentions to begin clinical investigation (human trials) for CB 182,804, a Cubist-discovered, potent, cidal, IV lipopeptide in development as therapy for the treatment of multi-drug resistant (MDR) Gram-negative infections, and CB-183,315, a Cubist-discovered, potent, oral, cidal lipopeptide in development for the treatment of Clostridium difficile associated diarrhoea.
The details can be read here.
No comments:
Post a Comment